Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuankai Shi

Showing results (201-210 of 347) with videos related to

Pageof 35
Sort By:
Asia-Pacific Journal of Clinical Oncology|March 3, 2022
A new prognostic model including platelet/lymphocyte ratio and International Prognostic Score 3 for freedom from progression in patients with previously untreated advanced classical Hodgkin lymphomaYunxia Tao, Haizhu Chen, Yu Zhou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 13, 2020
Activity and Safety of Geptanolimab (GB226) for Patients with Unresectable, Recurrent, or Metastatic Alveolar Soft Part Sarcoma: A Phase II, Single-arm StudyYuankai Shi, Qiqing Cai, Yu Jiang, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|March 1, 2023
High-Throughput Peptide Arrays Identify Potential Diagnostic Autoantibody Signatures in Early-Stage Lung AdenocarcinomaRongrong Luo, Pei Zhong, Xiying Li, et al.
Thrombosis Research|January 28, 2023
Validation of the IMPROVE bleeding risk assessment model in surgical patients: Results from the DissolVE-2 StudyZhu Zhang, Kaiyuan Zhen, Weimin Li, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|April 25, 2014
[A phase II multicenter study to investigate R-ICE as a salvage therapy for relapsed diffuse large B-cell lymphoma]Ye Guo, Yu Chen, Xiaonan Hong, et al.
Asia-Pacific Journal of Clinical Oncology|July 13, 2022
The clinical features, treatment, and prognostic factors for peripheral T-cell lymphomas: A single-institution analysis of 240 Chinese patientsHaizhu Chen, Yunxia Tao, Yu Zhou, et al.
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu|May 21, 2016
Phase I study of chimeric anti-CD20 monoclonal antibody in Chinese patients with CD20-positive non-Hodgkin's lymphomaLin Gui, Xiaohong Han, Xiaohui He, et al.
Carcinogenesis|December 22, 2006
Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancerBailin Zhang, Tong Sun, Liyan Xue, et al.
BMC Cancer|May 27, 2022
Enhancement of the International prognostic index with β2-microglobulin, platelet count and red blood cell distribution width: a new prognostic model for diffuse large B-cell lymphoma in the rituximab eraHaizhu Chen, Qiaofeng Zhong, Yu Zhou, et al.
Future Oncology (London, England)|February 18, 2022
Prognostic role of red blood cell distribution width and platelet/lymphocyte ratio in early-stage classical Hodgkin lymphomaYunxia Tao, Yu Zhou, Haizhu Chen, et al.
Pageof 35

Showing results (201-210 of 347) with videos related to

Sort By:
Pageof 35
Asia-Pacific Journal of Clinical Oncology|March 3, 2022
A new prognostic model including platelet/lymphocyte ratio and International Prognostic Score 3 for freedom from progression in patients with previously untreated advanced classical Hodgkin lymphomaYunxia Tao, Haizhu Chen, Yu Zhou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 13, 2020
Activity and Safety of Geptanolimab (GB226) for Patients with Unresectable, Recurrent, or Metastatic Alveolar Soft Part Sarcoma: A Phase II, Single-arm StudyYuankai Shi, Qiqing Cai, Yu Jiang, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|March 1, 2023
High-Throughput Peptide Arrays Identify Potential Diagnostic Autoantibody Signatures in Early-Stage Lung AdenocarcinomaRongrong Luo, Pei Zhong, Xiying Li, et al.
Thrombosis Research|January 28, 2023
Validation of the IMPROVE bleeding risk assessment model in surgical patients: Results from the DissolVE-2 StudyZhu Zhang, Kaiyuan Zhen, Weimin Li, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|April 25, 2014
[A phase II multicenter study to investigate R-ICE as a salvage therapy for relapsed diffuse large B-cell lymphoma]Ye Guo, Yu Chen, Xiaonan Hong, et al.
Asia-Pacific Journal of Clinical Oncology|July 13, 2022
The clinical features, treatment, and prognostic factors for peripheral T-cell lymphomas: A single-institution analysis of 240 Chinese patientsHaizhu Chen, Yunxia Tao, Yu Zhou, et al.
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu|May 21, 2016
Phase I study of chimeric anti-CD20 monoclonal antibody in Chinese patients with CD20-positive non-Hodgkin's lymphomaLin Gui, Xiaohong Han, Xiaohui He, et al.
Carcinogenesis|December 22, 2006
Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancerBailin Zhang, Tong Sun, Liyan Xue, et al.
BMC Cancer|May 27, 2022
Enhancement of the International prognostic index with β2-microglobulin, platelet count and red blood cell distribution width: a new prognostic model for diffuse large B-cell lymphoma in the rituximab eraHaizhu Chen, Qiaofeng Zhong, Yu Zhou, et al.
Future Oncology (London, England)|February 18, 2022
Prognostic role of red blood cell distribution width and platelet/lymphocyte ratio in early-stage classical Hodgkin lymphomaYunxia Tao, Yu Zhou, Haizhu Chen, et al.
Pageof 35